GHK-Cu is a copper tripeptide that drives collagen synthesis at picomolar doses and reshapes a third of the human genome in study models.

What the GHK-Cu record actually shows

GHK-Cu stimulated collagen synthesis in human fibroblast cultures at picomolar concentrations, with stimulation beginning between 10^-12 and 10^-11 M and peaking near 10^-9 M — and it did so without changing the number of cells, marking a specific metabolic effect rather than simple proliferation ^[1]. That single 1988 finding is the seed of everything downstream: GHK-Cu is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence that binds one copper(II) ion (molecular weight 402.92 Da), and the same sequence sits inside the alpha-2(I) chain of type I collagen, so the body already uses it as a local repair signal.

The effects are broad. A Connectivity Map analysis reported that GHK alters expression of about 31.2% of human genes at a 50%-or-greater change threshold — 59% of those up, 41% down — with strong stimulation of the DNA-repair, antioxidant and ubiquitin-proteasome programs ^[2]. In the skin, GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin, and one review reported that topical GHK-Cu raised collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid ^[3].

The honest counterweight is the human evidence. Most of the mechanistic data is in vitro or in rodents; the strongest controlled human signals are small topical skin trials and a single 45-man hair-count study of a combination formula ^[4]. This site is a GHK-Cu research overview that keeps the strong preclinical record and the thin clinical record in the same frame — the copper-coordination chemistry, the dose-response numbers, and the gaps where human data does not yet exist.

GHK-Cu is not approved as a drug by any regulatory body. Topical Copper Tripeptide-1 is a legal cosmetic ingredient with a long safety record; injectable and systemic use is unapproved and research-only. What follows describes what was administered, to which species, at which dose, by which route — never a recommendation for any person.

GHK copper peptide: what the research describes

The GHK copper peptide is the copper(II) chelate of the tripeptide glycine-histidine-lysine, bound 1:1 through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen and a deprotonated amide nitrogen, leaving the lysine side chain free ^[6]. It was first isolated by Loren Pickart in 1973 as a plasma factor that caused aged human liver tissue to synthesize proteins the way younger tissue does; plasma levels then decline with age, from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 ^[3].

Functionally the molecule wears two hats. As a copper chaperone it delivers the metal that lysyl oxidase needs to cross-link collagen and elastin, and it carries superoxide-dismutase-like antioxidant behavior. As a signaling molecule it drives matrix synthesis directly in fibroblasts ^[1] and, across reviewed wound models, increases collagen, elastin, VEGF, FGF-2 and nerve growth factor while suppressing free radicals, TNF-alpha and TGF-beta-1 and chemoattracting repair cells such as macrophages and mast cells ^[6]. The copper is not optional decoration: in fibroblast cultures the copper-bound form stimulated MMP-2 while the copper-free peptide did not ^[7]. That is the throughline of the whole literature — a small endogenous peptide that becomes a repair signal once it picks up copper.

What a copper peptide is

A copper peptide is a short peptide that holds a copper ion through chelation — binding the metal at several coordination points so it is stabilized and its reactivity is tuned. GHK-Cu is the most-studied example: three amino acids, one copper(II), a molecular formula of C14H23CuN6O4+ and a CAS number of 89030-95-5. Under its cosmetic-ingredient name it appears on labels as Copper Tripeptide-1.

Chelation matters because free copper is a pro-oxidant. The GHK-Cu complex has a very high copper stability constant (log K around 16.4), far higher than free GHK, which is exactly why the chelate releases very little free copper and behaves as a controlled carrier rather than a loose metal ^[3]. An intact solution is blue-violet — the expected color of Cu(II) in this coordination environment — and a shift to brown or green signals oxidation or precipitation. The distinction between GHK vs GHK-Cu runs through the entire field, because copper coordination is required for most of the documented activity ^[7].

Copper peptide benefits reported in research

The copper peptide benefits reported in research cluster into three buckets, all measured in study models rather than recommended for use. The first is matrix remodeling: GHK-Cu stimulates fibroblast synthesis of collagen, elastin, glycosaminoglycans and decorin, and rebalances matrix metalloproteinases against their TIMP inhibitors so remodeling favors preservation rather than destruction ^[3][7]. The second is antioxidant and anti-inflammatory activity: across reviewed models the peptide suppresses free radicals, TNF-alpha and TGF-beta-1 while engaging Nrf2-driven cytoprotective enzymes ^[6].

The third is angiogenesis and trophic support. GHK-modified alginate hydrogels induced dose-dependent VEGF secretion from human mesenchymal stem cells via integrin alpha-6/beta-1 signaling, with no cytotoxicity from 1 to 500 ng/mL ^[11]. The gene-level reach underpins all three: the Connectivity Map signature shows up-regulation of repair, DNA-fidelity and antioxidant gene sets and strong stimulation of the ubiquitin-proteasome system (41 genes up, 1 down) ^[2]. These are reproducible findings in cells, scaffolds and rodents — the human translation is the open chapter, summarized on GHK-Cu safety and side effects.